OBJECTIVES: Patients with type-1 diabetes (T1D) can either use multiple daily injections or insulin pump therapy (IPT) to achieve glycemic control.  However, there is a lack of real-world data on the differences in these treatment options, particularly as they relate to effectiveness. The objective of this study was to investigate the relationship between IPT and HbA1c among patients with T1D. METHODS: Data from unique respondents from the 2009-2012 U.S. National Health and Wellness Surveys were used. Among respondents who reported a diagnosis of T1D and reported using insulin, those who reported using IPT were compared with those who were not using IPT on reported HbA1c levels using an ordered logistic regression model controlling for sociodemographic and health history differences.  RESULTS: A total of 1833 patients reported being diagnosed with T1D and were currently using insulin.  Of these patients, 495 reported using IPT (27.0%).  Patients using IPT had been diagnosed with T1D for longer (26.8 vs. 21.1 years) and were significantly more likely to be female (53.1% vs. 42.5%), be non-Hispanic white (85.9% vs. 68.3%), have an annual household income of $75K or more (28.3% vs. 19.2%), and possess health insurance (95.8% vs. 84.5%) (all p<.05). Patients using IPT also reported significantly lower levels of HbA1c (7.2% vs. 7.5%, p<.05). Adjusting for sociodemographic and health history differences, patients using IPT were significantly less likely to report HbA1c levels 9% or more (b=-0.80, OR=0.45, p<.05). CONCLUSIONS: Although T1D patients with greater health care access were more likely to use IPT, even after adjusting for these differences, a significant effect of IPT was observed on HbA1c.  These results suggest that IPT may be associated with greater real-world effectiveness, though additional research is necessary.